ClinConnect ClinConnect Logo
Search / Trial NCT06455020

Catheter Ablation of Haemodynamically Not-tolerated Electrical Storm in Structural Heart Disease

Launched by BEIJING ANZHEN HOSPITAL · Jun 7, 2024

Trial Information

Current as of November 07, 2025

Not yet recruiting

Keywords

Catheter Ablation Mortality Electrical Storm

ClinConnect Summary

This clinical trial is looking at a treatment option for patients who experience a specific kind of heart problem called ventricular tachycardia (VT). VT can cause the heart to beat very fast and can be dangerous, especially if it results in low blood pressure, which means the heart isn't pumping enough blood to the body. The trial will compare two approaches: one group will receive a quick treatment called catheter ablation, while the other group will follow standard treatment methods. The goal is to see which method works better in helping patients who are experiencing serious symptoms from VT.

To be eligible for this trial, participants must be between 18 and 80 years old and have a type of heart disease. They need to have frequent episodes of VT, which means having more than three episodes in a day, and they must be experiencing low blood pressure during these episodes. However, people with certain heart conditions or recent heart surgeries, among other criteria, won't be able to participate. If you join the trial, you’ll be closely monitored by healthcare professionals, and they will provide you with care according to the study's protocols. This trial is important because it may help improve treatment options for patients with severe heart rhythm issues.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Patients aged 18 to 80 years;
  • 2. Having structural heart disease, including ischemic cardiomyopathy and nonischemic cardiomyopathy;
  • 3. Haemodynamically not-tolerated, defined as persistent hypotension (systolic blood pressure \<90 mmHg and mean arterial pressure 30 mmHg lower than baseline or \<70 mmHg, with associated signs of end-organ hypoperfusion);
  • 4. Electrical storm, defined as \>3 VT episodes within 24 hours.
  • Exclusion Criteria:
  • 1. Reversible causes of ventricular tachycardia or cardiomyopathy;
  • 2. Ventricular thrombosis diagnosed by echocardiography and/or cardiac magnetic resonance;
  • 3. Acute ST-segment-elevation myocardial infarction within 60 days;
  • 4. Cardiac surgery within 60 days;
  • 5. Unstable angina;
  • 6. Pregnancy.

About Beijing Anzhen Hospital

Beijing Anzhen Hospital is a leading medical institution in China, renowned for its expertise in cardiovascular diseases and comprehensive healthcare services. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical research and innovation, facilitating the development of new therapies and treatment protocols. With a focus on patient safety and ethical standards, Beijing Anzhen Hospital collaborates with various research entities to conduct rigorous clinical studies aimed at improving patient outcomes and enhancing the understanding of cardiovascular health. Its commitment to excellence in clinical research is underscored by a multidisciplinary team of experienced healthcare professionals and a state-of-the-art facility equipped to support a wide range of clinical investigations.

Locations

Nanjing, China

Beijing, China

Changsha, China

Kunming, China

Patients applied

0 patients applied

Trial Officials

Deyong Long, MD

Principal Investigator

Beijing Anzhen Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported